Although beneficial effects were not observed in a phase II trial for metastatic colorectal cancer [39], the efficacy of RO6874281 (an FAP-antibody fused with IL-2) is currently under clinical evaluation (NCT03424005, NCT03193190, NCT03386721, NCT02627274, NCT03063762, NCT03875079). Here, IL2 is linked to metastatic colorectal cancer.